Alexandria Venture Investments and 6 Dimensions Capital have participated in an oversubscribed second round for immunotherapy developer TCR2 Therapeutics.
US-based immuno-oncology drug developer TCR2 Therapeutics raised $125m yesterday in a series B round co-led by 6 Dimensions Capital, the investment firm backed by medical research firm WuXi PharmaTech.
The oversubscribed round was co-led with venture capital firm Curative Ventures and also featured Alexandria Venture Investments, the VC arm of life science real estate investment trust Alexandria Real Estate Equities.
MPM Capital, Redmile Group, ArrowMark Partners, Hillhouse Capital, MiraeAsset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital,…
